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ABSTRACT
Head and neck cancer (HNC) is a challenging tumour site for radiotherapy delivery owing to its complex anatomy and
proximity to organs at risk (OARs) such as the spinal cord and optic apparatus. Despite significant advances in
radiotherapy planning techniques, radiation-induced morbidities remain substantial. Further improvement would require
high-quality imaging and tailored radiotherapy based on intratreatment response. For these reasons, the use of MRI in
radiotherapy planning for HNC is rapidly gaining popularity. MRI provides superior soft-tissue contrast in comparison with
CT, allowing better definition of the tumour and OARs. The lack of additional radiation exposure is another attractive
feature for intratreatment monitoring. In addition, advanced MRI techniques such as diffusion-weighted, dynamic
contrast-enhanced and intrinsic susceptibility-weighted MRI techniques are capable of characterizing tumour biology
further by providing quantitative functional parameters such as tissue cellularity, vascular permeability/perfusion and
hypoxia. These functional parameters are known to have radiobiological relevance, which potentially could guide
treatment adaptation based on their changes prior to or during radiotherapy. In this article, we first present an overview of
the applications of anatomical MRI sequences in head and neck radiotherapy, followed by the potentials and limitations of
functional MRI sequences in personalizing therapy.
INTRODUCTION
Radical radiotherapy (RT) is integral to the management of
head and neck cancer (HNC) in both the primary and
adjuvant settings. Advances in computer-assisted radio-
logical techniques over the past two decades have in turn
revolutionized radiotherapy planning. Development of
advanced radiotherapy planning techniques such as
intensity-modulated radiotherapy (IMRT) and volumetric-
modulated arc therapy have allowed for better dose con-
formation to the tumour target and sparing of surrounding
normal tissues. HNC was one of the ﬁrst tumour sites
where IMRT was widely implemented owing to a signiﬁ-
cant reduction in radiation-induced xerostomia in com-
parison with three-dimensional conformal planning.1
CT is currently the standard platform for radiotherapy
planning. CT, however, provides a poor soft-tissue contrast,
resulting in difﬁculty in identifying tumour and organs at
risk (OARs) in the head and neck regions. On the contrary,
MRI utilizes a strong magnetic ﬁeld to provide high-resolution
anatomical information by which blood vessels, masses and
adjacent soft tissues are easily distinguishable. There is no
increased risk of secondary malignancies with repetitive
imaging, making MRI an attractive tool in the ﬁeld of
image-guided and adaptive radiotherapy.
The potential advantages of using MRI as a stand-alone
radiotherapy planning platform have led to international
collaboration to develop MR-Linac. MR-Linac aims to
combine the two technologies in the MRI scanner and
linear accelerator to address the current insufﬁciency in
modern image-guided radiotherapy, i.e. to accurately de-
ﬁne the tumour and tailor radiotherapy beams in real time.
This would help eliminate the uncertainties related to pa-
tient setup, intrafraction and interfraction movements.
However, there are several technical challenges with MR-
Linac such as the lack of electron density data and the
inﬂuence of magnetic ﬁeld on radiotherapy dose distribu-
tion due to secondary electrons, which are currently being
addressed during its development.
In addition, advanced MRI sequences, such as diffusion-
weighted (DW), dynamic contrast-enhanced (DCE) and in-
trinsic susceptibility-weighted (ISW) sequences are capable of
characterizing tumour biology further by providing quantitative
functional parameters that are known to have radiobiological
signiﬁcance such as tissue cellularity, vascular perfusion/
permeability and hypoxia. These sequences, also collectively
referred to as functional MRI (F-MRI) in this article, are areas of
ongoing research; but, there is increasing evidence to support
the role of these F-MRI parameters as predictive and prognostic
biomarkers.
In the ﬁrst section of this article, we give an overview of the
applications of anatomical MRI sequences in the management of
HNC with speciﬁc focus on radiotherapy. For the purpose of
this review, the term HNC refers primarily to squamous cell
carcinoma, which accounts for over 90% of head and neck
malignancies. Next, we elaborate on each F-MRI modality and
discuss their potential utilities and limitations as imaging bio-
markers to guide treatment individualization for HNC.
ANATOMICAL MRI SEQUENCES
Staging
MRI is increasingly used for deﬁning the extent of tumour in-
vasion into adjacent structures in HNC owing to its superior
soft-tissue contrast. T1 weighted images are generally considered
the best for gross structural information, whereas T2 weighted
images distinguish abnormal pathology from surrounding tis-
sues. In clinical practice, MRI is the imaging modality of choice
for staging primary disease for nasopharyngeal and sinonasal
tumours. It is also increasingly used to stage oropharyngeal (OP)
cancer and detect cartilage invasion for laryngeal/
hypopharyngeal cancer.2
MRI is also more reliable than CT at detecting the presence of
pre-vertebral space invasion,3 perineural spread4 and retro-
pharyngeal lymph node (LN) involvement,5 which are all im-
portant factors for treatment decision-making. A study by
Samuels et al6 demonstrated retropharyngeal node involvement
to be an independent poor prognostic feature, even for human
papilloma virus (HPV)-driven OP cancer. Figure 1 shows an
example of a metastatic retropharyngeal LN which was readily
detectable on MRI, but not on CT.
Radiotherapy planning—tumour target and organ at
risk delineation
Prior to the era of IMRT/volumetric-modulated arc therapy,
head and neck radiotherapy planning has been historically based
on compartmental volume, deﬁned by anatomical boundaries.
Consequently, radiation-induced toxicities were substantial with
signiﬁcant negative impact on patient quality of life. Advances in
both diagnostic imaging and planning techniques have permit-
ted a shift of practice towards volumetric contouring. This
means that high-dose clinical target volume only includes the
gross tumour volume (GTV) with a pre-determined margin for
isotropic expansion, instead of the whole anatomical subsite.
Importantly, no detrimental effect on locoregional control was
observed with volumetric contouring.7–9
Several planning studies have underlined the beneﬁt of in-
corporating MR images in head and neck radiotherapy planning
with improvement of tumour delineation and reduction in in-
terobserver variations compared with CT.10–12 It also enables
a more accurate delineation of neurological OARs such as the
spinal cord, brain stem, optic chiasm and hippocampus, which
is vital to avoid irreversible neurological sequelae. Nevertheless,
the accuracy of MRI in this context is hugely dependent on the
scanning position. Appropriate neck immobilization for plan-
ning MRI is necessary to reduce the risk of geographical miss, as
deformable registration is unable to fully account for the dif-
ferences in the position of the neck.13,14 Acquiring MRI in neck
immobilization requires deviation from standard protocol owing
to inability to use the standard head coil. However, this can be
overcome by using a combination of ﬂex and spine coils.15
The majority of commonly used metallic implants, including
dental objects, are MRI safe or conditional and can be imaged
with MRI. However, these objects may cause local magnetic ﬁeld
Figure 1. An example of axial T2 weighted MR image showing contralateral retropharyngeal node involvement (b) (indicated by
arrow) in a patient with left tonsillar squamous cell carcinoma, which was not readily visible on CT (a).
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inhomogeneity, resulting in regional signal loss and “pile-ups”
depending on the implant material and geometry.16 In practice,
these effects are often less problematic in comparison with CT
streak artefact caused by beam hardening and photon starvation,
thereby providing further advantage in radiotherapy planning.
Furthermore, these artefacts can be greatly reduced for MRI by
employing dedicated metal artefact reduction sequences, albeit
at the expense of longer acquisition times.17
In addition, it is feasible to quantify the magnitude of tumour
motion using cine-MRI. This enables an individualized internal
margin to generate a planning target volume for each patient. Cine-
MRI is acquired through continuous real-time imaging, which
historically posed limitations with poor image quality in terms of
spatial resolution and signal-to-noise ratio, but this has vastly im-
proved with newer techniques.18 A study assessing deglutition-
induced organ motion with cine-MRI observed some tumour
motion even in the absence of swallowing.19 The use of a custom-
ized intraoral immobilization device could help minimize tongue
movement and prevent swallowing,20 but this service requires input
from specialized orthodontics and is not widely available.
Radiotherapy delivery—adaptive approach
A patient anatomy changes throughout the course of radio-
therapy, which may signiﬁcantly alter the dose distribution to
both planning target volume and OARs. This is a prominent
issue for HNC owing to treatment-related weight loss. For ex-
ample, parotids are known to shrink up to 30–40% of their
original volume and tend to displace medially throughout the
course of radiotherapy.21,22 Adaptive radiotherapy studies with
CT have already demonstrated the beneﬁt of such an approach
in reducing cumulative dose to normal tissues throughout the
radiotherapy without compromising long-term outcome.23–25
MRI is naturally the imaging modality of choice for this ap-
proach owing to lack of additional radiation exposure and better
soft-tissue contrast. Current imaging modalities available in the
treatment room such as cone-beam CT or in-room CT provide
limited soft-tissue contrast which precludes precise tumour
tracking. One of the projected beneﬁts with MR-Linac is that
patients could be imaged daily to allow real-time online
matching, dosimetric analysis and plan reoptimization if re-
quired. Moreover, GTV could be modiﬁed based on tumour
response during radiotherapy, enabling further reduction in
dose to adjacent organs (Figure 2). Efforts to develop automated
OAR segmentation and rapid adaptive replanning are ongoing.
Functional MRI sequences
It is now evident that HNC represents a disease spectrum, which is
divisible into different prognostic groups based on clinical variables
such as clinical/radiological staging (Tumor, Node and Metastases),
HPV status and smoking history. There is, therefore, a pressing need
for a more personalized approach to treatment decision-making in
order to optimize the balance between therapeutic efﬁcacy and tox-
icity. However, biomarkers which could provide reliable information
on the likely impact of a speciﬁc intervention at an early time point
are required to guide treatment adaptation. F-MRI offers an attractive,
non-invasive means to characterize the tumour biology by providing
quantitative parameters with known radiobiological relevance. This
has, in turn, led to a surge in the number of studies investigating
the role of these parameters as imaging biomarkers for HNC over the
past decade. In this section, we review the evidence and discuss the
potential roles of these F-MRI sequences in the management of HNC.
Diffusion-weighted MRI
DW MRI utilizes the Brownian motion of water to assess tissue
cellularity without the need of any exogenous contrast agent.
Figure 2. The coronal T2 weighted MR images on the left are illustrating the early anatomical changes in primary gross tumour
volume (GTV) observed following Week-1 and Week-2 radical chemoradiotherapy (CRT) in a patient with human papilloma virus-
positive T3N0M0 left tonsillar squamous cell carcinoma. The axial image on the right is showing an overlay of co-registered MRIs
between pre-treatment and Week-2 CRT for the same patient to illustrate the potential benefit of dose reduction to the pharyngeal
constrictors and left parotid through GTV adaptation during radiotherapy with the shrinkage of the tumour away from these
structures (filled contour—Week-2 CRT; dotted contour—pre-treatment).
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The movement of the tissue water molecules during the course
of the diffusion-encoding gradients results in dephasing,
depicted as signal loss. The signal loss is proportional to the
amount of water molecule displacement and the duration of the
diffusion-encoding gradients (b-value). The voxel-based signal
loss can be quantiﬁed to produce maps of apparent diffusion
coefﬁcient (ADC), which is inversely correlated with tumour
cellularity.26
DW sequences are increasingly incorporated in routine head
and neck imaging owing to their additional values to ana-
tomical sequences at diagnosing primary tumours (PTs),
nodal involvement and detecting recurrences.27 Vandecaveye
et al28 further reported the ability of DW MRI to differentiate
between tumour and post-radiotherapy changes, thus
enabling identiﬁcation of residual tumour immediately after
radiotherapy, in contrast to ﬂudeoxyglucose-positron emis-
sion tomography (PET) which has a poor speciﬁcity in this
situation.29 The high contrast between tumour and
surrounding tissues in heavily DW images has also raised the
possibility to use this technique as an adjunct to guide GTV
delineation. Nevertheless, this is hampered by geometric
distortions which are pronounced in the head and neck re-
gion owing to the large magnetic ﬁeld inhomogeneity caused
by the tissue–air interface. A study by Schakel et al30 found
distortions up to 26mm in the anteroposterior axis. This,
however, can be minimized with dedicated acquisition and
post-processing methods.31,32 DW distortion in HNC was
shown to be greatly compensated using reduced-distortion
readout-segmented echoplanar imaging33 and half-Fourier
acquisition single-shot turbo spin echo (Figure 3). The latter,
however, may not be optimal for qualitative tumour assess-
ment owing to a low interobserver agreement for ADC values
in lesions assessed with conventional echoplanar imaging vs
half-Fourier acquisition single-shot turbo spin echo
techniques.34
There are now much published data that support the ability of
DW MRI to assist in the early prediction of treatment out-
comes following chemoradiotherapy in HNC. Overall, there
were conﬂicting results over the value of pre-treatment ADC at
predicting response to treatment (Table 1). Five studies failed
to distinguish patients with unfavourable disease based on pre-
treatment ADC,35–39 whereas six studies found high pre-
treatment tumour ADC to be predictive of poor outcome
following RT.40–45 As illustrated in Table 1, there are hetero-
geneities between the studies in scanning protocol, analytical
methods and measured clinical end points, which may be
Figure 3. A comparison of geometrical fidelity in head and neck diffusion-weighted (DW) images using conventional single-shot
echoplanar imaging (SS-EPI) and the readout-segmented echoplanar imaging (RESOLVE). DW sequences were acquired in the
axial plane, reformatted to the sagittal plane and overlaid with a T2 weighted anatomical sequence. Geometrical distortion resulting
in stretching or misslocation of anatomical signal can be observed in the SS-EPI sequence (inferior part of the spinal cord,
cerebellum and position of lymph nodes). A high geometrical fidelity can be observed in the corresponding images acquired using
RESOLVE (highlighted by the arrows).
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Table 1. Summary of diffusion-weighted (DW) MRI biomarker studies in head and neck cancer
Study
Design and
treatment
modalities
Scan
time
points
DW
scanning
protocol
Number of
patients/
ROIs
analyzed/
primary
sites
End points
(response
criterion)
Results
Suggested
ADC—
thresholds
Kim
et al40 (2009)
Prospective,
CRT
Pre-RT,
Week 1
and Week
2 RT
1.5 T or 3.0 T;
TR/TE:
4 s/89ms
(b5 0, 500,
1000 smm22)
33 patients (all
Stage IV)/LNs
only 66%
oropharynx
CR vs PR based
on clinical and
pathological
evidence
post-CRT
CR group has
a lower
pre-treatment
ADC
1.113 102
3mm2 s21
CR group has
a larger increase in
ADC post-Week 1
(,0.01) and
post-Week 2
RT (,0.05)
None
Kato
et al43 (2009)
Retrospective,
neoadjuvant
CRT, IC
and RT
Pre-RT
only
1.5 T; TR/TE:
5 s/70–72ms
(b5 0,
1000 smm22)
28 patients
(Stage II–IV)/
both PTs and
LNs 40%
larynx/
hypopharynx
Tumour
regression rate
(RECIST)
post-treatment
Inverse correlation
of pre-treatment
ADC with tumour
regression rate
(r520.384)
None
Vandecaveye
et al49 (2010)
Prospective,
CRT and RT
Pre-RT,
Week 2
and Week
4 RT
1.5 T; TR/TE:
7.1 s/84ms
(b5 0, 50,
100, 500, 750,
1000 smm22)
30 patients
(Stage I–IV)/
both PTs and
LNs 53%
larynx/
hypopharynx
Locoregional
control (median
follow-up
2 years)
Lower increase in
PTs and LNs ADC
2 and 4 weeks
after treatment is
associated with
poor locoregional
control at 2 years
PTs: 14%
(Week 2)
and 25%
(Week 4)
LNs: 14.6%
(Week 2)
and 19%
(Week 4)
Hatakenaka
et al41 (2011)
Retrospective,
CRT and RT
Pre-RT
only
1.5 T; TR/TE:
3 s/73ms
(b5 0, 300,
1000 smm22)
38 patients (17
Stage $III)/
PTs only 60%
hypopharynx/
larynx
LC vs local
failure (median
follow-up
approximately
10 months)
LC group has
a lower
pre-treatment
ADC
0.883 1023
mm2 s21
King
et al36 (2010)
Prospective,
CRT and RT
Pre-RT,
Week 2
RT and
6 weeks
post-RT
1.5 T; TR/TE:
2 s/75ms
(b5 0, 100,
200, 300, 400,
500 smm22)
50 patients
(Stage III–IV)/
single-slice
ADC analysis
of tumour
with largest
diameter
.50%
hypopharynx
Locoregional
control (median
follow-up
22 months)
No signal for
pre-treatment
ADC
N/A
A fall in ADC
during RT
predicts for local
failure
None
Ohnishi
et al48 (2011)
Retrospective,
CRT and RT
Pre-RT
only
1.5 T; TR/TE:
3 s/73ms;
(b5 0, 300,
1000 smm22)
32 patients,
(Stage I–IV)/
PTs only 53%
hypopharynx,
47%
oropharynx
LC (median
follow-up
15 months)
Low
pre-treatment
ADC predicts
for LC
0.793 1023
mm2 s21
Berrak
et al38 (2011)
Retrospective,
IC1CRT
Pre-IC
and
3 weeks
post-IC
1.5 or 3.0 T;
TR/TE:
4 s/89ms
(b5 0, 500,
1000 smm22)
18 patients
(Stage IV)/
LNs only 72%
oropharynx
OS (median
follow-up
approximately
19 months)
No signal for
pre-treatment
ADC
N/A
Alive—increase in
ADC 22%,
deceased—
decrease in
ADC 33%
None
(Continued)
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accountable for the discrepancy in their ﬁndings. Some inves-
tigators used different magnetic ﬁeld strengths (1.5Tor 3.0T) even
within the same study and the number of b-values used ranged
from 2 to 5. Whilst almost all studies excluded apparent tumour
necrosis from ADC calculation, there is a lack of consensus on
the analytical methods: some studies only chose the tumour
with the largest diameter (primary or LN), whereas others analyzed
them in isolation. However, the pre-treatment ADC thresholds
suggested by the positive studies appear to be fairly concordant
with primary ADC ,0.79–0.8831023mm2 s21 and nodal ADC
,1.11–1.1431023mm2 s21 to be predictive of favourable out-
come following radiotherapy.40,41,44,45 A contradictory result
by Nakajo et al,46 where they found patients with low pre-
treatment primary ADC ,0.883 1023mm2 s21 to have an
unfavourable 2-year outcome, somewhat highlighted the
potential negative inﬂuence of including inhomogeneous
tumour sites and treatment modalities in the study ﬁndings:
54% patients undergoing primary surgery instead of radio-
therapy, with higher recurrence rate in patients undergoing
surgery.
Table 1. (Continued)
Study
Design and
treatment
modalities
Scan
time
points
DW
scanning
protocol
Number of
patients/
ROIs
analyzed/
primary
sites
End points
(response
criterion)
Results
Suggested
ADC—
thresholds
Chawla
et al35 (2013)
Prospective,
CRT and
IC1CRT
Pre-RT
only
1.5 T or 3.0 T;
TR/TE:
4 s/89ms
(b5 0, 500,
1000 smm22)
24 patients
(Stage III–IV)/
both PTs and
LNs 94%
oropharynx
Responders vs
partial/
non-responders
(median
follow-up
23.7 months)
No signal from
pre-treatment
ADC alone (LN
and PTs)
N/A
Matoba
et al37 (2014)
Prospective,
CRT
Pre-RT
and Week
3 RT
1.5 T; TR/TE:
4 s/68ms
(b5 0, 90,
800 smm22)
35 patients
(Stage III–IV)/
both PTs and
LNs 57%
larynx/
hypopharynx
Locoregional
control (median
follow-up
30.8 months)
No signal from
pre-treatment
ADC
N/A
A larger increase
in PT ADC at
Week 3 RT
predicts for LC
24% increase
in PT ADC
Ng
et al42 (2014)
Prospective,
CRT
Pre-RT
only
3.0 T; TR/TE:
8.2 s/84ms
(b5 0,
800 smm22)
69 patients
(Stage III–IV)/
LNs only
(largest) 53%
oropharynx,
47%
hypopharynx
3-year neck
control (median
follow-up
31 months)
Higher
pre-treatment LN
ADC is an
independent
predictor of poor
neck control
1.143 1023
mm2 s21
Ng
et al45 (2016)
Prospective,
CRT
Pre-RT
only
3.0 T; TR/TE:
8.2 s/84ms
(b5 0,
800 smm22)
86 patients
(Stage III–IV)/
both PTs and
LNs 52%
oropharynx,
48%
hypopharynx
PFS and OS
(median
follow-up
36 months)
Lower LN ADC is
an independent
predictor of longer
PFS but not OS
1.143 1023
mm2 s21
PT ADC is
not an
independent
predictor factor
for PFS or OS
N/A
Wong
et al39 (2016)
Prospective,
IC1CRT
Pre-IC,
post-1st
and 2nd
cycle IC
1.5 T; TR/TE:
13 s/61ms
(b5 50, 400,
800 smm22)
20 patients
(Stage III–IV)/
both PTs and
LNs 90%
oropharynx
and 10%
larynx/
hypopharynx
Complete
remission
3 months
post-CRT
(median
follow-up
14 months)
No signal from
pre-treatment
ADC or
changes post-IC
N/A
ADC, apparent diffusion coefficient; CR, complete response; CRT, radical chemoradiotherapy; IC, induction chemotherapy; LC, local control; LN, lymph
node; N/A, not applicable; OS, overall survival; PFS, progression-free survival; PR, partial response; PT, primary tumour; ROI, region of interest; RT,
radical radiotherapy; TE, echo time; TR, repetition time.
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Another noteworthy observation by Wong et al39 is that HPV-
positive OP tumours in patients who achieved complete re-
mission following chemoradiotherapy exhibited a wide range
of pre-treatment ADC (0.9–1.543 1023 mm2 s21), thereby
undermining its predictive value. HPV-positive OP cancer
(tonsil and base of tongue) is known to exhibit unique his-
topathological features such as indistinct cell borders and
comedo necrosis, unlike other subsites or HPV-negative
disease.47,48 These features may have contributed to the
high ADC in some HPV-positive tumours but, importantly,
they do not have the same negative biological impact on
treatment outcome as on a patient who is HPV negative.48
The potential impact of HPV status on ADC measurements in
OP cancer has not been explored in other published studies;
hence, caution should be exercised when interpreting pre-
treatment ADC alone.
Whilst the value of pre-treatment ADC remains unclear,
treatment-induced changes of ADC during radiotherapy have
been more consistently demonstrated in several clinical
studies.36,37,40,49 The cumulative results suggest that tumours
that show a lower increase or even a decrease in ADC 1–4 weeks
into radiotherapy (ΔADC ,14–24%) are more likely to fail
treatment. It is speculated that tumours with a good treatment
response show a higher frequency of apoptosis or necrosis earlier
in the course of treatment than those with a poor response.
Thus, the ADC tends to increase in responding tumours because
of the presence of fewer barrier structures to the movement of
tissue water such as cell membranes. The optimal timing for
early intratreatment assessment using DW MRI, however, still
needs to be established (between Week 1 and Week 4 of RT), as
development of mature scar tissues may “falsely” decrease ADC
in responders.50
The majority of published studies have calculated mean or
median ADC from deﬁned regions of interest to quantitate
the observed differences in DW MRI between patients at
baseline and during treatment. More sophisticated analyses of
DW MRI data are possible and may enable DW MRI to be
used as a more sensitive and speciﬁc biomarker to provide an
early prediction of response to chemoradiotherapy. Galban
et al51 described a voxelwise approach to the evaluation of
ADC changes during treatment that involves the calculation
of parametric response maps (PRM) in 12 patients. This ap-
proach uses registered baseline and intratreatment ADC maps
to calculate regional tumour response and they concluded
that PRM may be more sensitive to cellular changes than
measurements of the change in the mean ADC over whole
regions of interest. One lingering uncertainty, however, is how
well deformable image registration accounts for volumetric or
positional changes in tumour between the scanning time
points to allow conﬁdent per-voxel analysis. Moreover, de-
formable image registration itself remains a matter of research
with lack of clinical validation. Further studies on larger
numbers of patients are, therefore, required.
Dynamic contrast-enhanced MRI
DCE MRI assesses changes in signal intensity following the in-
jection of a paramagnetic contrast agent, e.g. gadolinium that
shortens the longitudinal relaxation time (T1). This leads to
increased signal intensity in perfused tissue regions in T1
weighted images. The temporal changes in signal intensity
obtained by DCE MRI are related to the underlying permeability
and perfusion of tumour microenvironment, all of which are
known to inﬂuence treatment response. The gadolinium
concentration–time curve can also be ﬁtted to a two-
compartment pharmacokinetic model to yield various kinetic
and volumetric parameters such as the transfer coefﬁcient from
plasma to the interstitial space (Ktrans), the extracellular extra-
vascular volume fraction (Ve) and plasma volume fraction (Vp).
Enhancement patterns of DCE MRI have shown correlations
with malignancy,52 angiogenesis,53 proliferation54 and
hypoxia.55,56 One of the ﬁrst studies to evaluate the relationship
between tumour perfusion and local control (LC) using DCE
MRI in patients with HNC was published by Hoskin et al.57
13 patients underwent DCE MRI before and on completion of
accelerated radiotherapy. LC was found to be related to maxi-
mum tumour enhancement following radiotherapy and the
difference in time taken to reach maximum tumour enhance-
ment pre- and post-radiotherapy. These results suggested that
tumours with lower perfusion at the end of radiotherapy were
most sensitive to treatment and those with greater tumour en-
hancement were likely to fail locally.
Since then, several other groups have evaluated the ability of pre-
treatment DCE parameters to provide prognostic information
for patients with HNC undergoing radical chemoradiotherapy
(CRT). These studies have been summarized in two systematic
reviews published in recent years.58,59 The most commonly
reported pre-treatment DCE parameters with predictive or
prognostic value are Ktrans, followed by Ve and Vp. Two earlier
clinical studies have shown low pre-treatment nodal tumour
Ktrans to be correlated with poor locoregional control and
disease-free survival.60,61 No threshold was suggested, but non-
responders in both studies have an average Ktrans value of
0.15–0.21min21. However, one of the larger study to date by
Shukla-Dave et al62 reported that it was the skewness rather than
the mean value of nodal tumour Ktrans which was the strongest
predictor of progression-free survival (PFS). The authors
therefore recommended calculation of skewness to be a better
measure of tumour heterogeneity, but did not indicate whether
a positive or negative skew predicted for a better outcome.
Another large multimodality, parametric functional imaging
study of 69 patients by Ng et al42 reported low pre-treatment
nodal Ve (,0.23) to be an independent poor prognostic factor
for 3-year neck control for patients undergoing CRT. This is one
of the ﬁrst study reported in HNC to incorporate multimodality
functional imaging in ﬂuorine-18 ﬂudeoxyglucose-PET/CT,
DCE and DW MRI, given emerging evidence from correlation
studies that these modalities provide different, but comple-
mentary biological tumour information,63 thereby improving
predictive power. It is noteworthy that none of these studies
reported DCE parameters for PTs and this may be related to
technical difﬁculties, e.g. motion caused by swallowing or sus-
ceptibility artefacts. A more recent study by King et al64 in
49 patients assessed the predictive value of pre-treatment DCE
Review article: MRI in head and neck radiotherapy BJR
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parameters in both primary and nodal tumours but failed to
show any correlation with response to chemoradiotherapy. Ng
et al45 also provided an update on their previous study after
recruiting additional 17 patients and including PT in analysis.
This showed a similar result, i.e. low pre-treatment nodal Ve
independently predicted for shorter PFS and overall sur-
vival (OS).
It is possible to conclude from the cumulative results shown
above that pre-treatment DCE-derived Ktrans or Ve in LNs could
predict for outcome following radiotherapy in HNC. However, it
is impossible to deduce which are the optimal pre-treatment
parameters and the inconsistencies in the reported results are
invariably attributable to the differences in DCE scanning pro-
tocols, pharmacokinetic models and arterial input function
used. For example, there are up to four methodologies available
to estimate arterial input function, e.g. population averaged,65
reference tissue based,66 contrast concentration in adjacent
arteries67 and independent component analysis.68 Consequently,
large collective efforts are required to optimize and standardize
DCE protocols for future studies.
In contrast, there is a paucity of data on the role of intratreat-
ment DCE MRI to assess and predict response to radiotherapy.
The number of patients in these studies are very small (n, 15),
precluding any deﬁnitive conclusion or clinical translation. One
of the ﬁrst study by Cao et al69 reported an increase of blood
volume (BV) in PT 2 weeks into chemoradiotherapy to be as-
sociated with LC. Wang et al70 subsequently reported on
a cluster analysis method to identify biologically relevant tu-
mour subvolumes using DCE MRI. The sizes of the cluster
analysis-deﬁned tumour subvolumes with low BV, before and
during Week-2 radiotherapy, were signiﬁcantly greater in the
patients with local treatment failure (LF) than that in those with
LC. Whilst the total PT volumes were reduced from baseline to
Week 2 to a similar extent for both patients with LF and LC, the
percentage decreases in the subvolumes of the PTs with low BV
in the same time interval were signiﬁcantly smaller for the
patients with LF than that for those with LC (p, 0.05).70 This
illustrates the potential utility of DCE parameters to identify
a biological target volume for radiotherapy dose escalation and
using it to monitor response.
Baer et al71 investigated the feasibility of using PRM of DCE MRI
to predict survival following CRT in 10 patients. They found that
the reduction in Ktrans per voxel measured through PRM after
2 weeks of radiotherapy was a better predictor of OS in com-
parison with the whole tumour mean or median signal changes.
Similar to the DW PRM study, this needs to be validated with
more patients. The authors themselves acknowledged that the
process to analyze PRM is complex and requires special attention
during delineation owing to limitations in image resolution.
Intrinsic susceptibility-weighted MRI
Hypoxia is a well-recognized factor of resistance to chemo-
therapy and radiotherapy in HNC. A meta-analysis has dem-
onstrated hypoxia modiﬁcation to be a valid therapeutic
strategy;72 thus, a non-invasive mean to detect tumour hypoxia
is highly desirable to guide identiﬁcation of patients who are
likely to beneﬁt from such a strategy. PET-based techniques
using tracers such as ﬂuorine-18 ﬂuoromisonidazole are cur-
rently the most widely studied functional imaging to charac-
terize hypoxia in HNC. However, these PET techniques are
expensive, time consuming and suffer from a poor spatio-
temporal resolution and signal-to-noise ratio.73
An alternative hypoxia-speciﬁc imaging technique is ISW MRI,
also known as blood oxygen level-dependent MRI. It exploits the
paramagnetic properties of deoxyhaemoglobin in erythrocytes to
create contrast. Essentially, deoxyhaemoglobin creates magnetic
susceptibility perturbations around blood vessels and the
transverse MR relaxation rate R2* (R2*5 1/T2*) of water in
blood and the surrounding tissues increases in proportion to
tissue deoxyhaemoglobin concentration. Because oxygenation of
haemoglobin is proportional to arterial blood polarographic
oxygen levels, tumour R2* is a sensitive index of tissue oxy-
genation and a surrogate marker of hypoxia.
ISW MRI has been typically performed by measuring changes in
R2* with hyperoxic gas challenge such as carbogen. Clinical
studies conducted in patients with HNC have consistently dem-
onstrated that the tumour R2* decreases following inhalation of
hyperoxic gas, indicative of improved blood oxygenation which
may further increase the radiosensitivity.74,75 The use of hyperoxic
gas breathing in clinical practice remains limited owing to added
complexity and side effects such as breathlessness. However, there
are now emerging data that suggest that useful information may
still be obtained from ISW MRI, even in the absence of oxygen
challenge. A study in cervical cancer by Li et al76 was one of the
ﬁrst studies to demonstrate the ability of using baseline tumour
R2* alone to predict response to chemoradiotherapy: responders
had a lower baseline R2* than non-responders. This study also
found baseline R2* to be an independent prognostic factor for
PFS and OS. However, these results are yet to be replicated in
other tumour sites.
A study by Panek et al77 has demonstrated tumour R2* mea-
surement to be a sensitive and reproducible quantitative imaging
technique in detecting clinically relevant changes in tumour ox-
ygenation for HNC. However, reliable interpretation of R2* as
a stand-alone parameter is not possible without additional in-
formation such as tumour BV.77 This is supported by other
observations that hypoxic tumours with high blood ﬂow had high
R2*,
78 whereas hypoxic tumours with low BV were found to have
low R2* instead.
79 Serial weekly changes in R2* alone throughout
chemoradiotherapy in patients with HNC also did not appear to
show any clear pattern.80 Therefore, a better understanding of
how to interpret R2* measurements with BV needs to be ascer-
tained to improve its performance as an imaging biomarker.
Challenges with integration of functional MRI into
clinical practice
Whilst there is little doubt that F-MRI can provide predictive
and prognostic information for HNC, its integration into clin-
ical practice remains limited. One of the main reasons is the lack
of consensus of optimal modalities, scanning protocols and
analytical methodologies, leading to discrepancy in the reported
results (as described above). This is partly due to the constant
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evolution of machinery and acquisition techniques over the
years. Consequently, a meta-analysis of F-MRI studies is not
possible for the same reason. Efforts to standardize these pro-
tocols for clinical trials are under way and may be further fa-
cilitated through collaboration between MR-Linac consortiums.
Another important issue to consider is that physiological
parameters, such as perfusion and oxygenation, are dynamic and
potentially unstable parameters that may ﬂuctuate signiﬁcantly
in the absence of therapy. Only limited data exist on the stability
of F-MRI parameters in patients with cancer prior to treatment
and there are no data on this aspect that are speciﬁc to patients
with HNC receiving primary CRT. However, two studies in
patients with a variety of cancers enrolled in Phase 1 clinical drug
trials do provide some reassuring data on the reproducibility of
F-MRI parameters. Koh et al81 found ADC measurements from
DW-MRI to be highly reproducible, with a coefﬁcient of re-
peatability of 13.3%. Messiou et al82 also reported the intrapatient
coefﬁcients of variation (CVs) for all DCE-derived parameters to
be within the range of 8–30%, except for Vp.
82 The most re-
producible DCE-derived parameters were the enhancing fraction
(CV5 8.6%), followed by Ktrans (CV5 13.9%) and initial
area under the time-concentration curve over 60 seconds
(CV5 15.5%). The stability of these parameters in HNC need to
be established further prior to clinical implementation.
Furthermore, integration of F-MRI into radiotherapy treatment
planning requires special attention in terms of image quality and
geometrical accuracy, which means that image acquisition with
immobilization in the radiotherapy treatment position is es-
sential. This approach was lacking in most earlier F-MRI studies,
which precluded the analysis of PT owing to gross motion ar-
tefact. Consequently, tolerability may be an issue for some
patients owing to the additional discomfort with immobilization
and scanning time required in comparison with standard ana-
tomical MRI. Considerations should also be given to the po-
tential pressure on the hospital resources, e.g. time on scanners
and additional expertise required to process F-MRI images.
CONCLUSION
Anatomical and functional imaging capabilities offered by MRI
provide potential opportunities to optimize radiotherapy strat-
egies for HNC through improved target delineation, high-risk
disease subvolume identiﬁcation, early intratreatment monitor-
ing and adaptation based on response (Figure 4). Based on
current evidence, baseline tumour vascular permeability/
hypoxia and early cell apoptosis during radiotherapy, as measured
by DCE and DW MRI, respectively, appear to be the most
promising biomarkers to predict radiotherapy outcome and
tailor treatment strategies for HNC. The studies conducted to
date have laid a solid foundation for the exciting prospect of
integrating functional imaging into MR-Linac in the future.
This added dimension will further enhance the appeal of using
MRI as a single platform for radiotherapy planning and de-
livery in HNC. However, an important next step to bridge the
translational gaps for F-MRI is a collective effort to determine
the optimal methodology to allow standardization and perform
clinical validation through a large multicentre study.
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Figure 4. A schematic summarizing the potential applications of MRI in the management, radiotherapy planning and delivery of
head and neck cancer. BTV, biological target volume; DCE, dynamic contrast-enhanced; DW, diffusion-weighted; F-MRI, functional
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